#USA #Delray Beach #Drug Discovery #Biomedical Research #Humanized Models

Humanized Mouse and Rat Model Market Outlook

The global market for Humanized Mouse and Rat Models is poised for substantial growth over the coming years, valued at $255.8 million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 8.2%. By 2030, this market is expected to surpass $409.8 million, reflecting the increasing reliance on these models in pharmaceutical and biotechnology sectors.

Drivers of Market Growth

Several key factors are fueling the demand for humanized models, particularly in drug discovery research. The emergence of personalized medicine and extensive R&D activities in the pharmaceutical and biotechnology industries are contributing to this positive trend. As researchers continue to seek more accurate representations of human biology, the need for humanized mouse models has surged.

Humanized mouse models (hu-mice) are the leading segment within this market, projected to dominate revenue shares throughout the coming years. This surge is primarily because of advancements in genetic engineering technologies such as gene targeting and gene editing, enabling the creation of more effective models for biomedical research.

Application in Oncology

Oncology stands out as the largest application area within the humanized mouse and rat model market. A notable increase in cancer research funding and collaborative initiatives is directing substantial resources toward oncology studies using these advanced models. The growing emphasis on immuno-oncology research further highlights the importance of humanized models in understanding tumor behavior and treatment responses.

Segmentation of the Market

The humanized mouse and rat model market is segmented based on type, including humanized mouse models and humanized rat models. Within these categories, humanized mouse models are further divided into genetic and cell-based models, with genetic models generating the highest revenues in 2024.

By end users, the pharmaceutical and biotechnology companies emerge as the largest segment, actively utilizing these models to conduct extensive preclinical research. Contract Research Organizations (CROs) are another prominent user group, employing humanized models to provide insights into pharmacokinetics, safety, and efficacy of various compounds.

Geographic Insights

Regionally, North America has been a significant player in the humanized mouse and rat model market, but the highest growth is expected in the Asia-Pacific region. Rapid growth in countries like China and India, driven by increased research and development efforts and outsourcing activities, will likely contribute to this positive trend.

Key Players in the Market

Several companies lead the charge in the humanized mouse and rat model market: Charles River Laboratories, The Jackson Laboratory (JAX), and Taconic Biosciences, among others. These companies are leveraging strategic partnerships and acquisitions to enhance their service offerings and market presence.

• - Charles River Laboratories continues to innovate by acquiring companies like SAMDI Tech to streamline drug discovery processes.
• - genOway, renowned for its expertise in developing genetically engineered models, is forging partnerships with various pharmaceutical companies to expand its reach in biomedical research.

Conclusion

As the humanized mouse and rat model market continues to evolve, the interplay of technological advances, increasing research funding, and the drive for personalized medicine will shape its trajectory. With an annual growth of 8.2%, the market is set to attract significant investment and innovation, ensuring its pivotal role in future biomedical research and drug development efforts.